Clinical applications for Bril would include but not limited to prophylaxis, therapeutic, and as an adjunct combo to any complementary drug out there. That's practically three applications, but two should be enough since the IV portion could be easily repurposed for moderate, severe, and critically cv19 patients. The oral pill should suffice for many as a preventative and for mild or even moderate patients, to halt the progression to severe and critically ill patients.
Ipix could send shock waves if they decide to use Remdesivir as the placebo. They should. Practically, all nucleotide inhibitors are now useless! Bril is more likely to be effective than Leronlimab, Imo, since upregulation of defensin mimetics is enough to trigger an adaptive immune response to make its "indirect" antiviral effects but also in addressing severe patients with pneumonia and/or sepsis.
Now it will be interesting how TIH will look at this in terms of funding.
Will they run the IV portion only Or will they the po version as well for preventative? I expect grants and or funding to happen soon. A partnership could happen too as well, IMO. BRIL SHOULD ALSO WORK FOR OTHER PANDEMIC FLU, which is another business opportunity for IPIX.
Not worried about the next readout. It's in the bag already, some are just a bit slow or unable to assess or foresee things rather quickly; Pass the salt please!
If you find yourself betting against the company, what are you going to do about it? Checkmate! Both sides will catch fire and it's just a matter of time before this sp hits $1, $2, or higher. The valuation is very cheap here with IPIX and it's long overdue for a major correction!
My assumptions about their science have been spot on. The next readout will confirm that as well. GLTA.
We appreciate your business!
TAGB
